Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy



To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.

SparkCures ID 1092
Trial Phase Phase 2
Enrollment 4 Patients
Trial Sponsors
  • Cartesian Therapeutics
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Patients must be 18 years of age or older at the time of enrollment
  • High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs).

Exclusion Criteria:

  • Patients who are pregnant or lactating.
  • Patients who have any active and uncontrolled infection. No blood cultures are necessary unless clinically indicated.

US Trial Locations

Please visit the page for historical site information.

View Centers

Trial Links

Read the latest news and updates on this trial.

mRNA-Based CAR T-Cell Therapy Descartes-11 Moves Into Phase 2 Trial in Myeloma

March 08, 2021

Descartes-11 is part of Cartesian Therapeutics RNA ArmorySM, a cellular therapy platform that “enables mRNA-engineering any cell, to target to any tissue, any combination of therapies.” The platform utilizes autologous and allogeneic approaches to engineer products that optimize each therapy to different cell types. Moreover, the “army” of cells that is engineered deliver precision-targeted treatment directly to the myeloma cells with a defined half-life, which allows for repeat dosing and outpatient administration of some therapies.

The investigational Descartes-11 product is manufactured to express CAR molecules transiently rather than permanently, which could reduce some of the short- and long-term risks associated with traditional autologous CAR T-cell therapies.

Read more
SparkCures Verified

SparkCures is working closely with Cartesian Therapeutics to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors